Sensei Biotherapeutics (SNSE) Set to Announce Quarterly Earnings on Monday

Sensei Biotherapeutics (NASDAQ:SNSE – Get Rating) is scheduled to be announcing its earnings results on Monday, March 20th.

Sensei Biotherapeutics Price Performance

NASDAQ SNSE opened at $1.42 on Friday. The company has a 50 day simple moving average of $1.50 and a 200-day simple moving average of $1.54. The company has a debt-to-equity ratio of 0.01, a current ratio of 13.95 and a quick ratio of 13.95. The firm has a market capitalization of $43.62 million, a price-to-earnings ratio of -0.97 and a beta of -0.21. Sensei Biotherapeutics has a 52-week low of $1.30 and a 52-week high of $2.86.

Wall Street Analysts Forecast Growth

Separately, Citigroup started coverage on shares of Sensei Biotherapeutics in a research report on Tuesday, December 13th. They issued a “buy” rating for the company.

Hedge Funds Weigh In On Sensei Biotherapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC raised its holdings in shares of Sensei Biotherapeutics by 196.9% in the second quarter. Renaissance Technologies LLC now owns 247,000 shares of the company’s stock valued at $561,000 after buying an additional 163,805 shares during the last quarter. State Street Corp lifted its position in shares of Sensei Biotherapeutics by 7.3% during the 1st quarter. State Street Corp now owns 225,572 shares of the company’s stock worth $521,000 after buying an additional 15,280 shares during the last quarter. Millennium Management LLC lifted its position in shares of Sensei Biotherapeutics by 168.8% during the 2nd quarter. Millennium Management LLC now owns 133,705 shares of the company’s stock worth $304,000 after buying an additional 83,961 shares during the last quarter. Citadel Advisors LLC bought a new stake in shares of Sensei Biotherapeutics during the 2nd quarter worth $134,000. Finally, HighTower Advisors LLC bought a new position in Sensei Biotherapeutics in the first quarter valued at about $116,000. Institutional investors own 20.59% of the company’s stock.

Sensei Biotherapeutics Company Profile

(Get Rating)

Sensei Biotherapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways.